Bright Minds Biosciences Inc. (CSE:DRUG)

Bright Minds Biosciences Cash Flow Statement

Financials in millions CAD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Net Income	-27.35	-12.23	-2.8	-7.37	-14.96	-8.65
Depreciation & Amortization	0.07	0.08	0.07	0.07	0.01	-
Asset Writedown & Restructuring Costs	-	-	-	-	0	-
Stock-Based Compensation	4.88	3.18	0.84	1.15	0.9	0.88
Other Operating Activities	1.34	-0.28	-0	0.07	-0.26	0.14
Change in Accounts Payable	3.19	1.69	0.24	-1.2	0.77	0.51
Change in Other Net Operating Assets	-1.97	-1.13	-0.2	0.26	-0.04	-0.2
Operating Cash Flow	-19.83	-8.69	-1.85	-7.02	-13.59	-7.32
Long-Term Debt Repaid	-	-0.1	-0.09	-0.09	-0.01	-
Net Debt Issued (Repaid)	-0.1	-0.1	-0.09	-0.09	-0.01	-
Issuance of Common Stock	293.46	86.03	0.9	1.47	6	27.84
Other Financing Activities	-18.2	-0.36	-	0.8	-0.8	-1.79
Financing Cash Flow	275.16	85.57	0.81	2.19	5.2	26.06
Foreign Exchange Rate Adjustments	-1.31	0.31	0.01	-0.05	0.26	0.22
Net Cash Flow	254.01	77.19	-1.03	-4.88	-8.13	18.96
Levered Free Cash Flow	-13.1	-4.6	-0.69	-4.22	-7.58	-3.85
Unlevered Free Cash Flow	-13.07	-4.58	-0.69	-4.22	-7.58	-3.85
Change in Working Capital	1.22	0.55	0.04	-0.94	0.72	0.31

Source: S&P Global Market Intelligence. Standard template. Financial Sources.